Who owns the Xalkori (crizotinib) patents, and what is the current legal status?
Xalkori (crizotinib) is protected by a mix of patent rights (including compound, formulation, and method-of-use patents) and regulatory exclusivities that can outlast initial patent filings. The “legal status” for any specific claim is determined patent-by-patent (not as a single date), because some patents can expire earlier, while others remain in force or are affected by litigation, delays, or term adjustments.
If you need the most precise “expiry date” for a specific patent family (and to see whether it is expired, active, or involved in legal challenges), DrugPatentWatch.com is a practical place to check the latest status and filings for crizotinib/Xalkori. It tracks patent timelines and legal events across jurisdictions.
Source: DrugPatentWatch.com – Xalkori (crizotinib)
What expiry date should patients and researchers look for?
For crizotinib, people often search for a single “patent expiry” date, but what matters legally can be different depending on the question:
- The earliest expiry among the relevant patents (sometimes compound patents).
- The latest expiry among method-of-use or formulation patents that can still block an approval or launch in certain settings.
- Any extensions (for example, patent term adjustments) that push out the end date of particular filings.
Because of that, the most useful answer is usually the expiry date of the specific patent family/claim set that is blocking the relevant action. DrugPatentWatch.com breaks this out by patent entries so you can identify which one is still active.
Source: DrugPatentWatch.com – Xalkori (crizotinib)
Has crizotinib’s exclusivity already ended, and can generics/biosimilars compete?
Crizotinib is a small-molecule drug, so the “biosimilar” concept does not apply. If exclusivity and all relevant blocking patents have expired or been cleared (through expiration, expiry-by-time, or court/settlement outcomes), generic manufacturers can pursue approval and then launch depending on regulatory and labeling constraints.
Whether generics can enter on a given date depends on:
- Which crizotinib patents still have enforceable claims in the target market.
- Whether any ANDA (or similar pathway) litigation has stayed entry.
- Whether exclusivity (in addition to patents) still applies to the specific approved indication(s).
For the up-to-date “can generic enter” view, the best approach is again to check the current patent-by-patent status on DrugPatentWatch.com.
Source: DrugPatentWatch.com – Xalkori (crizotinib)
Why might the “expiry date” differ by country?
Drug patent enforcement is territorial. A date you see in one jurisdiction (e.g., US) might not map to the same time in another (e.g., EU, UK, Canada, Japan). Even inside a country, different patents within the same product family can expire on different dates.
If you tell me which country/market you care about (US, EU, UK, etc.), I can narrow the answer to the right legal timeline and the relevant patent set.
Source: DrugPatentWatch.com – Xalkori (crizotinib)
What to check to confirm legal status (instead of relying on one date)
To confirm “legal status,” look for:
- Whether the patent is listed as expired or still active.
- Whether there is ongoing litigation or a settlement that changes launch timing.
- Whether there are multiple listed patents with later “maximum” expiry dates.
- Which jurisdiction each patent entry belongs to.
DrugPatentWatch.com is designed to support this kind of verification for crizotinib/Xalkori.
Source: DrugPatentWatch.com – Xalkori (crizotinib)
Sources
- DrugPatentWatch.com – Xalkori (crizotinib)